Effect of clopidogrel after Percutaneous coronary intervention

Effect of clopidogrel after Percutaneous coronary intervention

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002167

Enrollment

Unknown

Registered

2012-05-11

Start date

2012-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary atherosclerotic heart disease

Interventions

A:Clopidogrel Hydrogensulfate Tablets

Sponsors

Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine

Lead Sponsor

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. patients who were diagnosed coronary heart disease by coronary angiography and who would underwent PCI; 2. application without clopidogrel contraindications

Exclusion criteria

Exclusion criteria: 1. allergies or contraindications to clopidogrel; 2. the risk of serious bleeding; 3. cancer; 4. pregnancy; 5. NYHA ? stage of heart failure.

Design outcomes

Primary

Measure	Time frame
Clopidogrel Resistance;gene polymorphis;	—

Countries

China

Contacts

Public ContactShu Meng

msdoctor@sohu.com+86 13916005250

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026